Haemodializált betegek anaemiájának kezelése rekombináns human erythropoietinnel.

Translated title of the contribution: Recombinant human erythropoietin in the therapy of anemia in hemodialyzed patients

G. Kakuk, I. Kárpáti, J. Mátyus

Research output: Contribution to journalReview article

2 Citations (Scopus)


The authors reported on a three month long EPREX (human recombinant erythropoietin) therapy of 5 hemodialysis patients for the treatment of their anemia. The drug was administered in bolus form 2 or 3 times a week after dialysis in a dose of 50 to 150 IU/bodyweight increased gradually in every (or every second) week. Hgb ad Htk values were determined once a week while erythrocyte, leukocyte, thrombocyte and reticulocyte count once a month. Serum iron, TIBC, serum ferritin, BUN, serum creatinine, urea, serum ions, liver function assays, serum lipids and amylase were also established. Hgb, Htk levels and reticulocyte count have significantly increased in the 4th week of treatment already, severe anemia ceased with improved appetite, general condition and physical strength. Serum urea and LDH levels significantly increased while SGOT decreased. No significant change in leukocyte and thrombocyte count, serum Na, K, Ca, P, Cl, BUN, creatinine, total protein level, serum albumin, bilirubin, alkaline phosphatase, GGT, GPT, amylase and blood sugar as well as serum lipid level were observed. No adverse reactions occurred during the treatment. After the three gradually decreased and within 6 weeks they had to be transfused again. In three patients the need for transfusion has significantly grown after the treatment. The authors consider EPREX a highly efficient drug in the treatment of anemia in dialysis patients.

Original languageHungarian
Pages (from-to)2365-2366, 2369
JournalOrvosi hetilap
Issue number43
Publication statusPublished - Oct 28 1990


ASJC Scopus subject areas

  • Medicine(all)

Cite this